Literature DB >> 3064716

Antitumor activity of the novel nitrosourea S10036 in rodent tumors.

S Filippeschi1, T Colombo, D Bassani, L De Francesco, P Arioli, M D'Incalci, I Bartosek, A Guaitani.   

Abstract

The activity of the novel anticancer agent diethyl 1-3-(chloroethyl)-3-nitrosoureido ethyl phosphonate (S10036) was investigated on several rodent tumors. S10036 showed a good efficacy, comparable to that of the anticancer agent BCNU, against i.p transplanted P388 and L1210 leukemias. S10036 was very effective against the primary tumor and metastases of i.m transplanted M5076 reticular cell sarcoma of the mouse and against subline A of the Walker carcinoma of the rat. It was inactive against rodent tumors resistant to BCNU such as L1210/BCNU, ICIG-Ci4 murine fibrosarcoma and the Walker carcinoma subline B in the rat.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3064716

Source DB:  PubMed          Journal:  Anticancer Res        ISSN： 0250-7005            Impact factor:   2.480


  6 in total

1.  Pharmacokinetics of fotemustine and BCNU in plasma, liver and tumor tissue of rats bearing two lines of Walker 256 carcinoma.

Authors:  A Guaitani; M Corada; C Lucas; A Lemoine; S Garattini; I Bartosek
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.

Authors:  Raffaele Addeo; Michele Caraglia; M Serena De Santi; Liliana Montella; Alberto Abbruzzese; Ciro Parlato; Bruno Vincenzi; Marco Carraturo; Vincenzo Faiola; Michele Genovese; Gregorio Cennamo; Salvatore Del Prete
Journal:  J Neurooncol       Date:  2010-08-10       Impact factor: 4.130

3.  Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives.

Authors:  Xavier Durando; Emilie Thivat; Michel D'Incan; Anne Sinsard; Jean-Claude Madelmont; Philippe Chollet
Journal:  BMC Cancer       Date:  2005-11-15       Impact factor: 4.430

4.  Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation.

Authors:  Alessandra Fabi; Giulio Metro; Michelangelo Russillo; Antonello Vidiri; Carmine Maria Carapella; Marta Maschio; Francesco Cognetti; Bruno Jandolo; Maria Alessandra Mirri; Isabella Sperduti; Stefano Telera; Mariantonia Carosi; Andrea Pace
Journal:  BMC Cancer       Date:  2009-03-31       Impact factor: 4.430

5.  Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

Authors:  Alba A Brandes; A Tosoni; E Franceschi; V Blatt; A Santoro; M Faedi; P Amistà; M Gardiman; R Labianca; C Bianchini; M Ermani; M Reni
Journal:  Cancer Chemother Pharmacol       Date:  2009-01-24       Impact factor: 3.333

6.  Fotemustine: a third-generation nitrosourea for the treatment of recurrent malignant gliomas.

Authors:  Patrick Beauchesne
Journal:  Cancers (Basel)       Date:  2012-02-01       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.